COCH Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 11.82%, SMA50 5.09%, SMA200 -34.57%). The stock’s 14-day RSI is 53.43 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -63.32% below its high and over 93.24% above its low. Average 10-day trading volume of 132.72 thousand shares is below the 3-month average of 787.00 thousand, indicating normal recent market interest.

Envoy Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.06. This means the shares are trading above this model’s fair value.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.50 to $2.50. The high target offers 284.62% upside. The low target suggests 284.62% downside. The mean target is $2.50. This offers 284.62% upside. Envoy Medical, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by 29.63%. The prior quarter beat by 10.34%. Over the last six quarters, Apple has recorded several small beats. These include 12.5% in August 12, 2024.

Envoy Medical, Inc. (NASDAQ:COCH) closed at $0.65 USD, losing -$0.02 (-3.05%) from the previous close of $0.67. The stock is currently mid-range between its 52-week high and low $0.36 and $1.91. With a market capitalization of about $13.60 million, Envoy Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.05). Key stats such as the average daily volume over the past year has been around 776.57 thousand shares, volume is running light vs its 52-week average. Headquartered in White Bear Lake, MN, Envoy Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Brent T. Lucas, the company employs approximately 42 people and listed since April 29, 2021. Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum.

Envoy Medical, Inc. has 21.52 million shares outstanding. The public float is 10.85 million shares, elevated short interest at 2.76% of float. This equals 301.39 thousand shares. The short ratio is 0.48 days. Institutional investors hold 117.24% of the float. Insiders own 49.46%. TAYLOR GLEN A holds 11.25 million shares, Anzu SPAC GP I LLC has 1.00 million shares and BRYNELSEN CHARLES has 600.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Envoy Medical, Inc. trades at a P/E ratio of -0.54, slightly below the S&P 500 average, with a price-to-sales ratio of 56.75 and a price-to-book ratio of -1.1 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.74, also below market averages.

Envoy Medical, Inc. (NASDAQ:COCH) shares are flat -0.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Envoy Medical, Inc. trading at a premium to the broader market with a P/E of -0.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.55, suggesting 1054.43% upside. Our AI forecast model points to short-term strength (2.45% over two weeks), a medium-term rise (51.38% over three months), and a longer-term gain (72.78% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Envoy Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.45%, with price expected at $0.67 by May 07, 2026, within a range of $0.60 to $0.74 3-Month Outlook: Projected rise of 51.38%, reaching $0.99 by July 22, 2026, with a range of $0.95 to $1.05. 1-Year Outlook: Projected gain of 72.78%, with price at $1.13 by April 23, 2027, within a range of $0.00 to $0.00.